Amneal Pharmaceuticals, Inc.

Plus, news about Avonik, a supply chain transparency bill and Nucleus RadioPharma: 💰 Amneal Pharmaceuticals to acquire biosimilar maker for $375M upfront : The generics and specialty drugmaker is set to buy Kashiv Biosciences in a deal that has up to $350 million in milestone payments. The transaction is expected to close in the second half of the year. 🇰🇷 Samsung Bio reports Q1 revenue as workers rally: Samsung Biologics on Wednesday said it pulled in 1.3 trillion Korean won ($878 million) in revenue for the first quarter of 2026, up 26% from the same period last year. The CDMO said the revenue uptick was driven by full “utilization” across its Plants 1 through 4. The report comes as the CDMO’s labor union held a 2,200-person rally on the same day over wage negotiations. Workers will strike on May 1 if Samsung Bio’s management continues to reject negotiations, the union said in a statement. 🇸🇮 Evonik’s Slovakia build: The pharma chemical maker is investing €80 million ($94 million) to expand its drug substance manufacturing services in Slovenská Ľupča. The expansion will create around 50 new jobs. 📜 New supply chain transparency bill introduced : The bipartisan bill , called the Drug Origin Transparency Act, has been created to give the FDA greater clarity into where prescription drugs and their active pharmaceutical ingredients are made. The draft legislation would require drug labels to identify the originating manufacturer and the API maker. The legislation was introduced by Reps. Doris Matsui (D-CA), Dan Crenshaw (R-TX), Ashley Hinson (R-IA) and Kim Schrier (D-WA). 💰 Nucleus RadioPharma secures $50M: The money is from the healthcare investment company OrbiMed. It will be used to expand a radiopharma factory in Rochester, MN, and support the development of a new facility in Philadelphia. Endpoints is fielding the next Biopharma Sentiment Index (BPSI) — a concise, three-minute survey that distills thousands of industry views into a clear quarterly benchmark. This year is pivotal for biopharma, and we need your perspective on where things are going. Take the survey here.

/ iStock, Dmitrii_Guzhanin The takeover will give Amneal control of four facilities to manufacture biosimilars for a planned wave of launches in the coming years. Amneal Pharmaceuticals has struck a $1.1 billion deal to buy Kashiv BioSciences, securing manufacturing capacity to support its ambition to become a global biosimilar leader. New Jersey-based Amneal has a long-standing relationship with Kashiv, licensing biosimilar copies of Amgen’s Neulasta and Neupogen from the company in 2017. Amneal won FDA approval for both the drugs in 2022, which it sells as Fylnetra and Releuko, respectively. The companies expanded their relationship in 2024, when Amneal licensed a Xolair biosimilar from Kashiv. Amneal’s co-CEOs—brothers Chirag and Chintu Patel—directly or indirectly own half of Kashiv. Amneal has agreed to buy Kashiv for $375 million in cash, $375 million in equity and up to $350 million in milestones, according to a Wednesday release. The deal will allow Amneal to integrate its biosimilar commercialization capabilities with the development and manufacturing infrastructure that already partly underpins its biologics business. Kashiv makes Fylnetra and Releuko at a facility in Chicago that has fill-finish capabilities. The Illinois plant is one of four facilities Amneal will acquire through the deal. Kashiv runs a facility in New Jersey with 6,000 L of capacity to make monoclonal antibodies and fusion proteins, plus two plants in India. Amneal will expand the sites to support its pipeline, committing to establishing 50,000 L of capacity at one of the Indian plants and increasing the volume of the New Jersey facility to 24,000 L. On an earnings call Wednesday, Amneal co-CEO Chintu Patel said drug substance capacity is expected to scale from 26,000 liters in 2026 to 75,000 by 2028. Patel added that Amneal anticipates $30 million to $50 million a year in capital expenditures to reach its capacity target. Manufacturing AbbVie commits $1.4B to NC plant in its largest-ever single campus investment The Durham plant will manufacture immunology, neuroscience and oncology drugs once AbbVie finishes construction in 2028. April 23, 2026 · 2 min read · Nick Paul Taylor Read more Amneal’s investments are intended to ensure capacity rises in line with demand from new biosimilar launches. After buying Kashiv, Amneal’s pipeline will include six biosimilars that could come to market by next year. The Xolair biosimilar is the biggest of the opportunities, accounting for $4.6 billion of a $14 billion total. The New Jersey plant will make the Xolair copy, according to Amneal’s other CEO Chirag Patel. The company could launch another six biosimilars with a total addressable market of $42 billion from 2028 to 2030. The figure reflects the almost $20 billion opportunity open to a copy of Merck’s Keytruda and the almost $10 billion market for a biosimilar version of Eli Lilly’s Trulicity. Amneal, which has won approval for five biosimilars in the past three years, wants to deliver three to five products a year. The cadence may demand ongoing investments in manufacturing. Chirag Patel said that the infrastructure is designed to allow Amneal to keep adding another 25,000 liters as needed once it hits its current target of 75,000 liters.

Amneal has boosted its presence in the biosimilars market with a $1.1 billion acquisition of Kashiv BioSciences. The industry is entering “the golden era for biosimilars,” Amneal co-CEO Chirag Patel said Wednesday morning as he explained the motivation for his company’s $1.1 billion acquisition of Kashiv BioSciences.In the merger of the New Jersey-based neighbors who conduct much of their manufacturing in India, generics leader Amneal is gaining biosimilars specialist Kashiv for $750 million upfront—split between cash and equity payable at close—plus up to $350 million in potential milestones. With its buyout of the 15-year-old private company, Anmeal’s share price increased by 5% by mid-morning on Wednesday. The companies expect the deal to close in the second half of this year.“The global market is expected to grow from about $40 billion today towards $200 billion by 2035, driven by the largest biologic loss of exclusivity in history,” Patel said during a conference call. “Biosimilars represent the next major wave of affordable medicines and we are at that inflection point. Patient access is expanding and the U.S. regulatory advancements are lowering development time and cost.” Kashiv brings two facilities in India, one for manufacturing and another for R&D. It also has a Chicago fill-finish plant and a manufacturing and R&D site at its headquarters in Piscataway, N.J. Kashiv currently boasts 25,000 liters of production capacity with plans to expand to 75,000 liters by 2028. The company also brings 600-plus employees.   In Chicago, Kashiv produces biosimilar versions of Amgen’s chemotherapy treatments Neupogen and Neulasta. By 2027, Amneal expects to be selling biosmilars to Roche’s Avastin, Amgen’s Xgeva and Prolia, and Roche and Novartis’ Avastin. The company expects to launch between three and five new biosimlars each year. By the end of 2029, Amneal expects to be selling biosimilars for several megablockbusters, including Merck’s Keytruda and Bristol Myers Squibb’s Opdivo.Amneal, which ranks among the world’s top 20 companies in sales of generics, also revealed its first-quarter results on Wednesday, with revenue reaching $723 million for a 4% year-over-year bump.The company generated sales of $3.02 billion in 2025 and is projecting revenue to increase between 1% and 4% this year. As the acquisition becomes accretive in 2027, the company expects sales to increase by between 7% and 13%. Amneal also took the unusual step of projecting its 2030 revenue, expecting it to land between $4.25 billion and $4.5 billion.  “For us to provide long-term guidance, we have to fell pretty confident in our ability to deliver on those commitments, number one,” Tasos Konidaris, Amneal's chief financial officer, said. “Number two, I think it speaks to the tremendous amount of diligence we have done with this acquisition.”